The UCLA Health Jonsson Comprehensive Cancer Center conducted a study that provides new evidence on how dietary changes can help to reduce the growth of cancer cells in active surveillance patients. Active surveillance is a form of treatment that includes regular monitoring and no immediate action. The study, which was published in Journal of Clinical Oncology in 19659001, showed that men in early stages of the disease who ate a low-omega-6 diet and a high omega-3 diet, along with supplements of fish oils, saw fewer prostate cancers. “
“This is an important step toward understanding how diet can potentially influence prostate cancer outcomes,” Dr. William Aronson is Professor of Urology and the first author of this study at UCLA’s David Geffen School of Medicine. “Many men are interested in lifestyle changes, including diet, to help manage their cancer and prevent the progression of their disease. Our findings suggest that something as simple as adjusting your diet could potentially slow cancer growth and extend the time before more aggressive interventions are needed.”
Although many men with prostate cancer of low risk choose to be monitored rather than immediately treated, after five years about half will need either radiation or surgery. Patients are therefore eager to discover ways to delay treatment. This includes dietary modifications or supplementation. Nevertheless, no specific guidelines have been established in this field. Other clinical trials examined healthy eating patterns and increased vegetable consumption, but none found that they had a major impact on cancer progression. The UCLA-led group conducted CAPFISH-3 to determine if diet and supplements could play a part in the management of prostate cancer. This trial included 100 men who had low or intermediate risk prostate carcinomas, but chose active surveillance. The participants were randomly assigned either to continue with their usual diet or to follow a diet high in omega-3 and low in omega-6 for one full year.
The intervention group received personalized dietary counseling from a dietician nutritionist in person, via telehealth, or over the phone. The patients were instructed on how to replace high-fat/high-calorie foods with healthier alternatives (such using lemon juice and vinegar in salad dressing) and reduce consumption of foods that contain more omega-6 (such cookies, chips, mayonnaise, and processed or fried foods). It was aimed at achieving a healthy balance between omega-6 fats and omega-3 fatty acids, and making participants feel confident about changing their behaviors. The participants were given extra Omega-3s in the form of fish oil capsules. Control group didn’t receive any diet counseling and did not take fish oil.
Researchers tracked changes to a biomarker known as the Ki-67 Index, which is a measure of how quickly cancer cells multiply — an important predictor for cancer progression, metastasis, and survival. The researchers used an image-fusion device to track the location of cancerous sites. They also obtained biopsies from the same site at the beginning and after a year. The results showed that the group with a low-omega-6 diet, an omega-3 rich fish oil and a high omega-3 intake had a decrease of 15% in Ki67, while the group without these factors saw a rise of 24%. Aronson is the chief of urologic cancer at West Los Angeles Veterans Affairs Medical Center, and a member of UCLA Health Jonsson Comprehensive Cancer Center. The researchers found that, while the results were promising, they did not see any difference in other growth markers for cancer, like Gleason grades, which are used commonly to monitor prostate cancer progression.
Investigators warn that more research is needed to confirm long-term effects of omega-3 and omega-6 fatty acids in the management of prostate cancer. These findings are in favor of larger, longer-term trials that explore the impact of diet on prostate cancer treatment, survival and progression. Susanne H. Henning is the senior author of this study. She was adjunct professor Emerita at UCLA and the former director for the Center for Human Nutrition’s nutritional biomarker lab. Tristan Grogan is another UCLA co-author, as are Dr. Pei LIang, Patricia Jardack and Amana Liddell. Claudia Perez also contributed to the study, along with Dr. David Elashoff. Jonathan Said, Dr. Leonard Marks, and Patricia Jardack.
This study was partially funded by Howard B. Klein, UCLA Health Jonsson Comprehensive Cancer Center and the Seafood Industry Research Fund.